Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

VCI Global Limited Announces Memorandum of Agreement to Acquire a 70% stake in LOCUS-T Sdn Bhd 20-04-2023, 20:19

NSERC Awards Funding to TRIUMF and General Fusion to Develop State-of-the-Art Diagnostic System for LM26 Fusion Machine 27-03-2024, 20:00